Clinical Studies and Case Reports

On this site you will find clinical studies with cannabis or single cannabinoids in different diseases and case reports on the use of cannabis by patients.
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.

[Back to Overview]  [IACM Homepage]

TitleImprovement in refractory psychosis with dronabinol: four case reports.
Author(s)Schwarcz G, Karajgi B.
Journal, Volume, IssueJ Clin Psychiatry. 2010 Nov;71(11):1552-3.
Major outcome(s)Significant improvement in four patients

no abstract available.

Summary from the IACM-Bulletin:In a letter to the editor of the Journal of Clinical Psychiatry doctors of the Rockland Psychiatric Center in Orangeburg, New York, USA, reported of four more patients with schizophrenia not responding to other medication, who improved considerably with a treatment by THC. The physicians had already published a similar experience with four other patients in 2009. This time they tried dronabinol (THC) for 8 further patients in the hospital. They all suffered from severe psychosis refractory to standard medication and reported of a positive previous experience with cannabis. There were four responders with good improvement with THC and four non-responders.

One case was a 54-year-old man with schizoaffective disorder, who had been aggressive, intrusive, and disorganized for years in spite of multiple medication trials. Before the THC trial he received daily clozapine, risperidone, lithium carbonate, and clonazepam for months with no significant benefit. After adding 5 mg THC twice a day he became calm, cooperative, and logical and was very much improved, as did the other three responders. None of the four non-responders had a worsening of their psychosis or other effects. Authors noted, that they "simply had no change with the addition of dronabinol." They write: "We suspect that in a small subsect of these [psychotic] patients, the etiology of their psychosis is low endogenous endocannabinoid brain function, so that cannabinoid stimulation would improve their behaviour."

Duration (days)
Participants8 patients with schizophrenia
DesignUncontrolled case report
Type of publicationMedical journal
Address of author(s)Rockland Psychiatric Center, Orangeburg, NY 10962, USA.
Full text

[Back to Overview]  [IACM Homepage]